Literature DB >> 27186317

Optogenetics for neurodegenerative diseases.

Kiara T Vann1, Zhi-Gang Xiong1.   

Abstract

Neurodegenerative diseases are devastating conditions that lead to progressive degeneration of neurons. Neurodegeneration may result in ataxia, dementia, and muscle atrophies, etc. Despite enormous research efforts that have been made, there is lack of effective therapeutic interventions for most of these diseases. Optogenetics is a recently developed novel technique that combines optics and genetics to modulate the activity of specific neurons. Optogenetics has been implemented in various studies including neuropsychiatric disorders and neurodegenerative diseases. This review focuses on the recent advance in using this technique for the studies of common neurodegenerative diseases.

Entities:  

Keywords:  Optogenetics; channelrhodopsin; halorhodopsin; neurodegenerative diseases

Year:  2016        PMID: 27186317      PMCID: PMC4859873     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  54 in total

1.  Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer.

Authors:  Hiroshi Tomita; Eriko Sugano; Hiromu Yawo; Toru Ishizuka; Hitomi Isago; Satoko Narikawa; Sebastian Kügler; Makoto Tamai
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-08       Impact factor: 4.799

2.  Chronic optogenetic activation augments aβ pathology in a mouse model of Alzheimer disease.

Authors:  Kaoru Yamamoto; Zen-Ichi Tanei; Tadafumi Hashimoto; Tomoko Wakabayashi; Hiroyuki Okuno; Yasushi Naka; Ofer Yizhar; Lief E Fenno; Masashi Fukayama; Haruhiko Bito; John R Cirrito; David M Holtzman; Karl Deisseroth; Takeshi Iwatsubo
Journal:  Cell Rep       Date:  2015-04-30       Impact factor: 9.423

3.  Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats.

Authors:  Hiroshi Tomita; Eriko Sugano; Hitomi Isago; Teru Hiroi; Zhuo Wang; Emi Ohta; Makoto Tamai
Journal:  Exp Eye Res       Date:  2009-12-27       Impact factor: 3.467

4.  Halorhodopsin is a light-driven chloride pump.

Authors:  B Schobert; J K Lanyi
Journal:  J Biol Chem       Date:  1982-09-10       Impact factor: 5.157

5.  Optogenetic activation of superior colliculus neurons suppresses seizures originating in diverse brain networks.

Authors:  Colin Soper; Evan Wicker; Catherine V Kulick; Prosper N'Gouemo; Patrick A Forcelli
Journal:  Neurobiol Dis       Date:  2015-12-23       Impact factor: 5.996

6.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

7.  Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation.

Authors:  Anke Brederlau; Ana Sofia Correia; Sergey V Anisimov; Muna Elmi; Gesine Paul; Laurent Roybon; Asuka Morizane; Filip Bergquist; Ilse Riebe; Ulf Nannmark; Manolo Carta; Erik Hanse; Jun Takahashi; Yoshiki Sasai; Keiko Funa; Patrick Brundin; Peter S Eriksson; Jia-Yi Li
Journal:  Stem Cells       Date:  2006-03-23       Impact factor: 6.277

8.  Restoring the ON Switch in Blind Retinas: Opto-mGluR6, a Next-Generation, Cell-Tailored Optogenetic Tool.

Authors:  Michiel van Wyk; Justyna Pielecka-Fortuna; Siegrid Löwel; Sonja Kleinlogel
Journal:  PLoS Biol       Date:  2015-05-07       Impact factor: 8.029

9.  Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury.

Authors:  Jeanne T Paz; Thomas J Davidson; Eric S Frechette; Bruno Delord; Isabel Parada; Kathy Peng; Karl Deisseroth; John R Huguenard
Journal:  Nat Neurosci       Date:  2012-11-07       Impact factor: 24.884

10.  Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model.

Authors:  Inna Sukhotinsky; Alexander M Chan; Omar J Ahmed; Vikram R Rao; Viviana Gradinaru; Charu Ramakrishnan; Karl Deisseroth; Ania K Majewska; Sydney S Cash
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

View more
  3 in total

Review 1.  CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury.

Authors:  Vera Paschon; Felipe Fernandes Correia; Beatriz Cintra Morena; Victor Allisson da Silva; Gustavo Bispo Dos Santos; Maria Cristina Carlan da Silva; Alexandre Fogaça Cristante; Stephanie Michelle Willerth; Florence Evelyne Perrin; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2020-01-11       Impact factor: 5.590

2.  Effect of Redox-Modifying Agents on the Activity of Channelrhodopsin-2.

Authors:  Bao-Ming Wu; Tian-Dong Leng; Koichi Inoue; Jun Li; Zhi-Gang Xiong
Journal:  CNS Neurosci Ther       Date:  2016-12-04       Impact factor: 5.243

Review 3.  Biophysical Properties of Optogenetic Tools and Their Application for Vision Restoration Approaches.

Authors:  Simon D Klapper; Anka Swiersy; Ernst Bamberg; Volker Busskamp
Journal:  Front Syst Neurosci       Date:  2016-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.